Hi Jay,
I called CYPB today. I spoke with someone who did not know enough about the prosorba technology to answer my questions. They put me in touch with their on-call nurse..who was out. I left her a message. I hope she calls back. All was not lost, they will send me the investor-press kit, though I doubt it will have the answers to my questions.
They are very basic. If you get through maybe run these by them:
1) The Prosorba column is based on the fact that Protein-A binds to the Fc portion of antibodies, right?
2) If that is the case, then there is no specificity for Rheumatoid Arthritis. Therefore, one could conceivably use the column for other auto-immune diseases. Examples include: Myasthenia gravis, Systemic Lupus, MS, some thyroid disorders.... Is Cypress considering applying for other indications of the Prosorba column? Which ones? Are there tests in progress? If not, why not?
3) Since the column removes antibodies from the circulation, does the treatment cause susceptibility to infections? If not, why not?
If I could get these answers I would feel more comfortable investing in some CYPB shares.
Does anyone have a financial evaluation of CYPB? I'd like to know how much cash assets they have, debt, and burn rate.
Thanks again.
I'll let you know if they get back to me about the above. |
